Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.